CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim

  • Posted by: BIOCON

Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India

  • Posted by: BIOCON

Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore

  • Posted by: BIOCON

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers

  • Posted by: BIOCON

JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment

  • Posted by: BIOCON

Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore

  • Posted by: BIOCON

FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab

  • Posted by: BIOCON

Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s 77th Scientific Sessions

  • Posted by: BIOCON

Biocon Appoints Ms. Pratima Rao as Mission Director of Biocon Foundation

  • Posted by: BIOCON

Kiran Mazumdar Shaw Felicitated with ‘AWSM Award for Excellence 2017’ by The Feinstein Institute for Medical Research, USA

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>